391 related articles for article (PubMed ID: 15231678)
1. Antiangiogenic and antitumoral activity of phenyl-3-(2-chloroethyl)ureas: a class of soft alkylating agents disrupting microtubules that are unaffected by cell adhesion-mediated drug resistance.
Petitclerc E; Deschesnes RG; Côté MF; Marquis C; Janvier R; Lacroix J; Miot-Noirault E; Legault J; Mounetou E; Madelmont JC; C -Gaudreault R
Cancer Res; 2004 Jul; 64(13):4654-63. PubMed ID: 15231678
[TBL] [Abstract][Full Text] [Related]
2. Microtubule disruption induced in vivo by alkylation of beta-tubulin by 1-aryl-3-(2-chloroethyl)ureas, a novel class of soft alkylating agents.
Legault J; Gaulin JF; Mounetou E; Bolduc S; Lacroix J; Poyet P; Gaudreault RC
Cancer Res; 2000 Feb; 60(4):985-92. PubMed ID: 10706114
[TBL] [Abstract][Full Text] [Related]
3. Alkylation potency and protein specificity of aromatic urea derivatives and bioisosteres as potential irreversible antagonists of the colchicine-binding site.
Fortin JS; Lacroix J; Desjardins M; Patenaude A; Petitclerc E; C-Gaudreault R
Bioorg Med Chem; 2007 Jul; 15(13):4456-69. PubMed ID: 17498960
[TBL] [Abstract][Full Text] [Related]
4. Alkylation of beta-tubulin on Glu 198 by a microtubule disrupter.
Bouchon B; Chambon C; Mounetou E; Papon J; Miot-Noirault E; Gaudreault RC; Madelmont JC; Degoul F
Mol Pharmacol; 2005 Nov; 68(5):1415-22. PubMed ID: 16099845
[TBL] [Abstract][Full Text] [Related]
5. In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton.
Hayot C; Farinelle S; De Decker R; Decaestecker C; Darro F; Kiss R; Van Damme M
Int J Oncol; 2002 Aug; 21(2):417-25. PubMed ID: 12118340
[TBL] [Abstract][Full Text] [Related]
6. Hypoestoxide, a natural nonmutagenic diterpenoid with antiangiogenic and antitumor activity: possible mechanisms of action.
Ojo-Amaize EA; Nchekwube EJ; Cottam HB; Bai R; Verdier-Pinard P; Kakkanaiah VN; Varner JA; Leoni L; Okogun JI; Adesomoju AA; Oyemade OA; Hamel E
Cancer Res; 2002 Jul; 62(14):4007-14. PubMed ID: 12124334
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the covalent binding of N-phenyl-N'-(2-chloroethyl)ureas to {beta}-tubulin: importance of Glu198 in microtubule stability.
Fortin S; Bouchon B; Chambon C; Lacroix J; Moreau E; Chezal JM; Degoul F; C-Gaudreault R
J Pharmacol Exp Ther; 2011 Feb; 336(2):460-7. PubMed ID: 20978170
[TBL] [Abstract][Full Text] [Related]
8. Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo.
Wong VK; Chiu P; Chung SS; Chow LM; Zhao YZ; Yang BB; Ko BC
Clin Cancer Res; 2005 Aug; 11(16):6002-11. PubMed ID: 16115945
[TBL] [Abstract][Full Text] [Related]
9. New soft alkylating agents with enhanced cytotoxicity against cancer cells resistant to chemotherapeutics and hypoxia.
Patenaude A; Deschesnes RG; Rousseau JL; Petitclerc E; Lacroix J; Côté MF; C-Gaudreault R
Cancer Res; 2007 Mar; 67(5):2306-16. PubMed ID: 17332362
[TBL] [Abstract][Full Text] [Related]
10. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
11. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
Kuo CC; Hsieh HP; Pan WY; Chen CP; Liou JP; Lee SJ; Chang YL; Chen LT; Chen CT; Chang JY
Cancer Res; 2004 Jul; 64(13):4621-8. PubMed ID: 15231674
[TBL] [Abstract][Full Text] [Related]
12. N-(4-iodophenyl)-N'-(2-chloroethyl)urea as a microtubule disrupter: in vitro and in vivo profiling of antitumoral activity on CT-26 murine colon carcinoma cell line cultured and grafted to mice.
Borel M; Degoul F; Communal Y; Mounetou E; Bouchon B; C-Gaudreault R; Madelmont JC; Miot-Noirault E
Br J Cancer; 2007 Jun; 96(11):1684-91. PubMed ID: 17486131
[TBL] [Abstract][Full Text] [Related]
13. N-Phenyl-N'-(2-chloroethyl)ureas (CEU) as potential antineoplastic agents. Part 2: role of omega-hydroxyl group in the covalent binding to beta-tubulin.
Fortin S; Moreau E; Patenaude A; Desjardins M; Lacroix J; Rousseau JL; C-Gaudreault R
Bioorg Med Chem; 2007 Feb; 15(3):1430-8. PubMed ID: 17118664
[TBL] [Abstract][Full Text] [Related]
14. Potential antagonism of tubulin-binding anticancer agents in combination therapies.
Taraboletti G; Micheletti G; Dossi R; Borsotti P; Martinelli M; Fiordaliso F; Ryan AJ; Giavazzi R
Clin Cancer Res; 2005 Apr; 11(7):2720-6. PubMed ID: 15814654
[TBL] [Abstract][Full Text] [Related]
15. Selective alkylation of beta(II)-tubulin and thioredoxin-1 by structurally related subsets of aryl chloroethylureas leading to either anti-microtubules or redox modulating agents.
Fortin JS; Côté MF; Lacroix J; Desjardins M; Petitclerc E; C-Gaudreault R
Bioorg Med Chem; 2008 Aug; 16(15):7277-90. PubMed ID: 18617414
[TBL] [Abstract][Full Text] [Related]
16. Effect of an aryl chloroethyl urea on tubulin and vimentin syntheses in a human breast cancer cell line.
Poyet P; Ritchot N; Béchard P; Gaudreáult RC
Anticancer Res; 1993; 13(5A):1447-52. PubMed ID: 8239518
[TBL] [Abstract][Full Text] [Related]
17. Chloroethyl urea derivatives block tumour growth and thioredoxin-1 nuclear translocation.
Patenaude A; Fortin JS; Deschenes R; Côté MF; Lacroix J; C-Gaudreault R; Petitclerc E
Can J Physiol Pharmacol; 2010 Nov; 88(11):1102-14. PubMed ID: 21076498
[TBL] [Abstract][Full Text] [Related]
18. Alkylation of prohibitin by cyclohexylphenyl-chloroethyl urea on an aspartyl residue is associated with cell cycle G(1) arrest in B16 cells.
Bouchon B; Papon J; Communal Y; Madelmont JC; Degoul F
Br J Pharmacol; 2007 Oct; 152(4):449-55. PubMed ID: 17704829
[TBL] [Abstract][Full Text] [Related]
19. Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain.
Juarez JC; Guan X; Shipulina NV; Plunkett ML; Parry GC; Shaw DE; Zhang JC; Rabbani SA; McCrae KR; Mazar AP; Morgan WT; Doñate F
Cancer Res; 2002 Sep; 62(18):5344-50. PubMed ID: 12235005
[TBL] [Abstract][Full Text] [Related]
20. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells.
Pasquier E; Honore S; Pourroy B; Jordan MA; Lehmann M; Briand C; Braguer D
Cancer Res; 2005 Mar; 65(6):2433-40. PubMed ID: 15781659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
